| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 29 | 2025 | 1798 | 2.670 |
Why?
|
| Breast Neoplasms | 52 | 2021 | 3147 | 2.280 |
Why?
|
| Randomized Controlled Trials as Topic | 27 | 2025 | 935 | 2.230 |
Why?
|
| Research Design | 12 | 2025 | 631 | 2.140 |
Why?
|
| Androgen Antagonists | 13 | 2025 | 144 | 1.940 |
Why?
|
| Antineoplastic Agents, Hormonal | 18 | 2024 | 154 | 1.890 |
Why?
|
| Neoplasm Recurrence, Local | 23 | 2024 | 1469 | 1.560 |
Why?
|
| Tamoxifen | 20 | 2014 | 171 | 1.470 |
Why?
|
| Brain Neoplasms | 9 | 2025 | 855 | 1.300 |
Why?
|
| Glioblastoma | 6 | 2025 | 286 | 1.280 |
Why?
|
| Proportional Hazards Models | 21 | 2024 | 901 | 1.200 |
Why?
|
| Neoplasms | 17 | 2025 | 3250 | 1.160 |
Why?
|
| Data Interpretation, Statistical | 9 | 2024 | 312 | 1.150 |
Why?
|
| Clinical Trials as Topic | 14 | 2025 | 1178 | 1.020 |
Why?
|
| Prostate-Specific Antigen | 11 | 2025 | 346 | 0.950 |
Why?
|
| Clinical Trials, Phase III as Topic | 6 | 2016 | 178 | 0.920 |
Why?
|
| Statistics as Topic | 2 | 2021 | 236 | 0.910 |
Why?
|
| Models, Statistical | 7 | 2025 | 594 | 0.900 |
Why?
|
| Survival Analysis | 21 | 2024 | 1546 | 0.790 |
Why?
|
| Disease-Free Survival | 30 | 2025 | 1195 | 0.790 |
Why?
|
| Humans | 131 | 2025 | 96127 | 0.730 |
Why?
|
| Obesity | 6 | 2021 | 1034 | 0.720 |
Why?
|
| Receptors, Estrogen | 17 | 2012 | 417 | 0.690 |
Why?
|
| Biomarkers, Tumor | 11 | 2019 | 1665 | 0.670 |
Why?
|
| Antineoplastic Agents | 13 | 2021 | 2422 | 0.660 |
Why?
|
| Middle Aged | 76 | 2025 | 28363 | 0.610 |
Why?
|
| Biomarkers | 4 | 2025 | 1933 | 0.610 |
Why?
|
| Aged | 61 | 2025 | 20964 | 0.610 |
Why?
|
| Biometry | 4 | 2025 | 72 | 0.540 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 12 | 2025 | 2642 | 0.520 |
Why?
|
| Male | 55 | 2025 | 45870 | 0.510 |
Why?
|
| Medical Futility | 1 | 2016 | 34 | 0.490 |
Why?
|
| Prognosis | 25 | 2024 | 4033 | 0.490 |
Why?
|
| Chemotherapy, Adjuvant | 14 | 2011 | 518 | 0.470 |
Why?
|
| Female | 75 | 2025 | 50063 | 0.470 |
Why?
|
| Risk Assessment | 14 | 2024 | 2480 | 0.470 |
Why?
|
| Salvage Therapy | 3 | 2024 | 238 | 0.470 |
Why?
|
| Colonic Neoplasms | 6 | 2016 | 589 | 0.450 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2015 | 156 | 0.440 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 270 | 0.420 |
Why?
|
| Radiation Oncology | 2 | 2016 | 125 | 0.410 |
Why?
|
| Odds Ratio | 11 | 2020 | 713 | 0.410 |
Why?
|
| Disease Progression | 10 | 2020 | 1568 | 0.400 |
Why?
|
| Neoplasm Staging | 19 | 2018 | 2081 | 0.400 |
Why?
|
| Treatment Outcome | 24 | 2024 | 9173 | 0.400 |
Why?
|
| Prostatectomy | 5 | 2024 | 480 | 0.390 |
Why?
|
| Body Mass Index | 5 | 2013 | 815 | 0.380 |
Why?
|
| Likelihood Functions | 3 | 2014 | 257 | 0.370 |
Why?
|
| Clinical Trials Data Monitoring Committees | 2 | 2016 | 5 | 0.360 |
Why?
|
| Medical Oncology | 3 | 2024 | 408 | 0.360 |
Why?
|
| Kaplan-Meier Estimate | 11 | 2018 | 886 | 0.360 |
Why?
|
| Time Factors | 16 | 2025 | 5585 | 0.360 |
Why?
|
| Lymph Nodes | 4 | 2012 | 565 | 0.350 |
Why?
|
| Survival Rate | 17 | 2017 | 1986 | 0.340 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1973 | 0.340 |
Why?
|
| Aged, 80 and over | 21 | 2025 | 7232 | 0.330 |
Why?
|
| Follow-Up Studies | 17 | 2024 | 3927 | 0.320 |
Why?
|
| Neoplasms, Second Primary | 5 | 2006 | 247 | 0.310 |
Why?
|
| Patient Compliance | 1 | 2011 | 239 | 0.310 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2011 | 504 | 0.300 |
Why?
|
| Cognition Disorders | 1 | 2011 | 244 | 0.300 |
Why?
|
| Adult | 35 | 2025 | 28718 | 0.300 |
Why?
|
| Estrogen Antagonists | 5 | 2004 | 48 | 0.300 |
Why?
|
| Lymphatic Metastasis | 11 | 2012 | 514 | 0.290 |
Why?
|
| Risk Factors | 16 | 2024 | 5960 | 0.280 |
Why?
|
| Multicenter Studies as Topic | 6 | 2012 | 183 | 0.280 |
Why?
|
| Health Status Disparities | 2 | 2011 | 221 | 0.280 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2020 | 286 | 0.280 |
Why?
|
| DNA Modification Methylases | 2 | 2025 | 32 | 0.260 |
Why?
|
| United States | 19 | 2025 | 7767 | 0.260 |
Why?
|
| DNA Repair Enzymes | 2 | 2025 | 61 | 0.260 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 6 | 2011 | 126 | 0.250 |
Why?
|
| Neoplasm Grading | 8 | 2024 | 404 | 0.250 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 2018 | 149 | 0.250 |
Why?
|
| Pleural Neoplasms | 3 | 2013 | 205 | 0.250 |
Why?
|
| Quality of Life | 6 | 2025 | 1816 | 0.250 |
Why?
|
| Combined Modality Therapy | 13 | 2025 | 1773 | 0.240 |
Why?
|
| Mesothelioma | 4 | 2013 | 333 | 0.240 |
Why?
|
| Cause of Death | 3 | 2019 | 278 | 0.240 |
Why?
|
| Health Services Accessibility | 4 | 2021 | 491 | 0.240 |
Why?
|
| Mastectomy, Segmental | 8 | 2011 | 108 | 0.230 |
Why?
|
| Genes, BRCA1 | 4 | 2008 | 192 | 0.230 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2025 | 301 | 0.220 |
Why?
|
| Drug Administration Schedule | 5 | 2018 | 873 | 0.220 |
Why?
|
| Radiotherapy Dosage | 4 | 2025 | 482 | 0.220 |
Why?
|
| Estrogen Receptor Modulators | 2 | 2003 | 10 | 0.220 |
Why?
|
| Endpoint Determination | 3 | 2020 | 59 | 0.220 |
Why?
|
| Incidence | 6 | 2022 | 1715 | 0.200 |
Why?
|
| Tosyl Compounds | 3 | 2021 | 13 | 0.200 |
Why?
|
| Radiotherapy | 6 | 2017 | 328 | 0.200 |
Why?
|
| Anilides | 3 | 2021 | 46 | 0.200 |
Why?
|
| Nitriles | 3 | 2021 | 157 | 0.190 |
Why?
|
| Mass Screening | 4 | 2019 | 710 | 0.190 |
Why?
|
| Radiation Pneumonitis | 1 | 2022 | 23 | 0.190 |
Why?
|
| Dacarbazine | 4 | 2017 | 101 | 0.190 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2002 | 166 | 0.190 |
Why?
|
| Neoplasm Metastasis | 8 | 2021 | 1103 | 0.180 |
Why?
|
| Rectal Neoplasms | 1 | 2003 | 134 | 0.180 |
Why?
|
| Immunotherapy | 2 | 2024 | 763 | 0.180 |
Why?
|
| Social Class | 2 | 2016 | 145 | 0.170 |
Why?
|
| Antineoplastic Agents, Alkylating | 4 | 2017 | 138 | 0.170 |
Why?
|
| Lung Neoplasms | 4 | 2022 | 2463 | 0.170 |
Why?
|
| Electronic Mail | 1 | 2020 | 17 | 0.170 |
Why?
|
| Pneumonia | 1 | 2022 | 197 | 0.160 |
Why?
|
| Coronavirus | 1 | 2020 | 20 | 0.160 |
Why?
|
| Kallikreins | 1 | 2020 | 46 | 0.160 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2012 | 172 | 0.160 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2024 | 292 | 0.160 |
Why?
|
| Hypersensitivity | 1 | 2022 | 166 | 0.160 |
Why?
|
| Treatment Failure | 4 | 2017 | 297 | 0.160 |
Why?
|
| Patient Readmission | 1 | 2024 | 413 | 0.160 |
Why?
|
| Longitudinal Studies | 3 | 2025 | 1175 | 0.160 |
Why?
|
| Confidence Intervals | 2 | 2014 | 220 | 0.160 |
Why?
|
| Head and Neck Neoplasms | 4 | 2011 | 1089 | 0.160 |
Why?
|
| Double-Blind Method | 9 | 2020 | 1791 | 0.160 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2018 | 1105 | 0.150 |
Why?
|
| Breast | 3 | 2013 | 297 | 0.150 |
Why?
|
| Risk | 5 | 2019 | 668 | 0.150 |
Why?
|
| Educational Status | 3 | 2020 | 202 | 0.150 |
Why?
|
| Biomedical Research | 1 | 2004 | 441 | 0.150 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2019 | 36 | 0.150 |
Why?
|
| Radiosurgery | 1 | 2022 | 316 | 0.150 |
Why?
|
| DNA Mismatch Repair | 1 | 2019 | 61 | 0.140 |
Why?
|
| Radiotherapy, Intensity-Modulated | 4 | 2025 | 188 | 0.140 |
Why?
|
| Cisplatin | 2 | 2018 | 611 | 0.140 |
Why?
|
| Tobacco Smoking | 1 | 2018 | 31 | 0.140 |
Why?
|
| Papillomavirus Infections | 2 | 2018 | 301 | 0.140 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2019 | 50 | 0.140 |
Why?
|
| Cetuximab | 1 | 2018 | 119 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2018 | 107 | 0.140 |
Why?
|
| Patient Participation | 1 | 2020 | 241 | 0.140 |
Why?
|
| Computer Simulation | 4 | 2014 | 1158 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2012 | 465 | 0.140 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2019 | 162 | 0.130 |
Why?
|
| Prospective Studies | 7 | 2022 | 4671 | 0.130 |
Why?
|
| Life Expectancy | 2 | 2009 | 91 | 0.130 |
Why?
|
| Receptors, Progesterone | 5 | 2012 | 195 | 0.130 |
Why?
|
| Healthcare Disparities | 2 | 2021 | 490 | 0.130 |
Why?
|
| DNA Methylation | 5 | 2025 | 703 | 0.130 |
Why?
|
| Cardiovascular Diseases | 1 | 2024 | 777 | 0.130 |
Why?
|
| Socioeconomic Factors | 4 | 2010 | 639 | 0.130 |
Why?
|
| Genes, BRCA2 | 2 | 2008 | 162 | 0.130 |
Why?
|
| SEER Program | 3 | 2019 | 235 | 0.130 |
Why?
|
| Electronic Health Records | 1 | 2020 | 372 | 0.120 |
Why?
|
| Internal-External Control | 1 | 2016 | 45 | 0.120 |
Why?
|
| Mammography | 4 | 2013 | 475 | 0.120 |
Why?
|
| Coronary Disease | 1 | 1997 | 263 | 0.120 |
Why?
|
| Religion | 1 | 2016 | 89 | 0.120 |
Why?
|
| Nomograms | 2 | 2012 | 35 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 346 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 334 | 0.110 |
Why?
|
| Probability | 1 | 2016 | 365 | 0.110 |
Why?
|
| Health Literacy | 1 | 2016 | 77 | 0.110 |
Why?
|
| Epidemiologic Research Design | 1 | 2014 | 23 | 0.110 |
Why?
|
| Registries | 3 | 2024 | 986 | 0.110 |
Why?
|
| Pandemics | 1 | 2020 | 880 | 0.110 |
Why?
|
| Regression Analysis | 2 | 2014 | 599 | 0.110 |
Why?
|
| ErbB Receptors | 3 | 2012 | 513 | 0.100 |
Why?
|
| Cohort Studies | 5 | 2022 | 3107 | 0.100 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2013 | 48 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2014 | 299 | 0.100 |
Why?
|
| alpha-Tocopherol | 1 | 2013 | 9 | 0.100 |
Why?
|
| Quality Assurance, Health Care | 2 | 2012 | 231 | 0.100 |
Why?
|
| Selenomethionine | 1 | 2013 | 11 | 0.100 |
Why?
|
| Retrospective Studies | 7 | 2024 | 10286 | 0.100 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 1172 | 0.100 |
Why?
|
| Cyclophosphamide | 4 | 2012 | 313 | 0.100 |
Why?
|
| Early Detection of Cancer | 2 | 2014 | 484 | 0.100 |
Why?
|
| Anticarcinogenic Agents | 1 | 2013 | 71 | 0.100 |
Why?
|
| Age Factors | 5 | 2020 | 1963 | 0.090 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2012 | 100 | 0.090 |
Why?
|
| Drug Dosage Calculations | 1 | 2012 | 16 | 0.090 |
Why?
|
| Drug Design | 1 | 2012 | 133 | 0.090 |
Why?
|
| Arsenic Poisoning | 1 | 2013 | 104 | 0.090 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2012 | 25 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2019 | 2473 | 0.090 |
Why?
|
| Body Weight | 3 | 2013 | 460 | 0.090 |
Why?
|
| Antioxidants | 1 | 2013 | 233 | 0.090 |
Why?
|
| Bias | 3 | 2025 | 139 | 0.090 |
Why?
|
| Predictive Value of Tests | 4 | 2020 | 1807 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 569 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2014 | 1020 | 0.080 |
Why?
|
| Stroke | 1 | 2000 | 1087 | 0.080 |
Why?
|
| Doxorubicin | 2 | 2012 | 304 | 0.080 |
Why?
|
| Comorbidity | 2 | 2024 | 1011 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 3 | 2008 | 590 | 0.080 |
Why?
|
| Chemoradiotherapy | 3 | 2018 | 328 | 0.080 |
Why?
|
| Decision Making | 3 | 2016 | 694 | 0.080 |
Why?
|
| Death Certificates | 1 | 2009 | 11 | 0.080 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 1215 | 0.080 |
Why?
|
| Genes, erbB-2 | 1 | 2009 | 25 | 0.080 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2010 | 63 | 0.080 |
Why?
|
| Pneumonectomy | 1 | 2012 | 220 | 0.080 |
Why?
|
| Neuropsychological Tests | 1 | 2011 | 549 | 0.070 |
Why?
|
| Neoadjuvant Therapy | 1 | 2012 | 444 | 0.070 |
Why?
|
| Quinazolines | 1 | 2010 | 216 | 0.070 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2025 | 315 | 0.070 |
Why?
|
| Population Surveillance | 1 | 2009 | 218 | 0.070 |
Why?
|
| Germ-Line Mutation | 2 | 2019 | 381 | 0.070 |
Why?
|
| Time | 1 | 2008 | 79 | 0.070 |
Why?
|
| Fanconi Anemia Complementation Group F Protein | 1 | 2007 | 6 | 0.070 |
Why?
|
| Ovariectomy | 1 | 2008 | 91 | 0.070 |
Why?
|
| Fallopian Tubes | 1 | 2008 | 49 | 0.070 |
Why?
|
| Skin Neoplasms | 1 | 2013 | 625 | 0.070 |
Why?
|
| Quality Improvement | 1 | 2012 | 502 | 0.070 |
Why?
|
| Prevalence | 2 | 2024 | 1349 | 0.070 |
Why?
|
| Analysis of Variance | 2 | 2012 | 910 | 0.070 |
Why?
|
| Colorectal Neoplasms | 2 | 2006 | 1069 | 0.070 |
Why?
|
| Mutation | 3 | 2008 | 4374 | 0.070 |
Why?
|
| Parent-Child Relations | 1 | 2007 | 83 | 0.060 |
Why?
|
| Disclosure | 1 | 2007 | 111 | 0.060 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2007 | 185 | 0.060 |
Why?
|
| Estrogen Receptor alpha | 1 | 2007 | 155 | 0.060 |
Why?
|
| Survival | 1 | 2006 | 21 | 0.060 |
Why?
|
| Flutamide | 2 | 2017 | 3 | 0.060 |
Why?
|
| Goserelin | 2 | 2017 | 5 | 0.060 |
Why?
|
| Disability Evaluation | 1 | 2007 | 171 | 0.060 |
Why?
|
| Vulnerable Populations | 1 | 2007 | 94 | 0.060 |
Why?
|
| Aneuploidy | 1 | 2005 | 64 | 0.060 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2025 | 18 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2005 | 109 | 0.060 |
Why?
|
| Proton Therapy | 2 | 2016 | 36 | 0.060 |
Why?
|
| Geriatric Assessment | 1 | 2007 | 192 | 0.060 |
Why?
|
| North America | 1 | 2005 | 199 | 0.060 |
Why?
|
| Ipilimumab | 1 | 2025 | 64 | 0.060 |
Why?
|
| Control Groups | 1 | 2025 | 16 | 0.060 |
Why?
|
| Bayes Theorem | 2 | 2014 | 404 | 0.060 |
Why?
|
| Brachytherapy | 1 | 2025 | 127 | 0.050 |
Why?
|
| Growth Inhibitors | 1 | 2004 | 41 | 0.050 |
Why?
|
| Technology, Radiologic | 2 | 2016 | 104 | 0.050 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2004 | 34 | 0.050 |
Why?
|
| Logistic Models | 2 | 2020 | 1268 | 0.050 |
Why?
|
| Statistics, Nonparametric | 1 | 2004 | 311 | 0.050 |
Why?
|
| Cancer Care Facilities | 1 | 2003 | 36 | 0.050 |
Why?
|
| Body Composition | 1 | 2003 | 75 | 0.050 |
Why?
|
| Travel | 1 | 2003 | 72 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2004 | 152 | 0.050 |
Why?
|
| Interprofessional Relations | 1 | 2004 | 128 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2004 | 137 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2011 | 1730 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2004 | 263 | 0.050 |
Why?
|
| Chicago | 2 | 2024 | 1503 | 0.050 |
Why?
|
| Lomustine | 2 | 2012 | 26 | 0.050 |
Why?
|
| Neoplasms, Experimental | 1 | 2004 | 271 | 0.050 |
Why?
|
| Cooperative Behavior | 1 | 2004 | 197 | 0.050 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2012 | 72 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2008 | 725 | 0.050 |
Why?
|
| Bevacizumab | 2 | 2014 | 276 | 0.050 |
Why?
|
| Young Adult | 2 | 2012 | 7025 | 0.050 |
Why?
|
| Interferon-gamma | 1 | 2004 | 467 | 0.050 |
Why?
|
| Consensus | 1 | 2004 | 370 | 0.040 |
Why?
|
| Hematuria | 1 | 2022 | 50 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2004 | 503 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2004 | 447 | 0.040 |
Why?
|
| Carcinoma in Situ | 2 | 1999 | 53 | 0.040 |
Why?
|
| Computational Biology | 1 | 2024 | 584 | 0.040 |
Why?
|
| Sex Factors | 1 | 2024 | 1133 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2025 | 451 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 713 | 0.040 |
Why?
|
| Selection Bias | 1 | 2020 | 38 | 0.040 |
Why?
|
| Monte Carlo Method | 2 | 2014 | 191 | 0.040 |
Why?
|
| Multivariate Analysis | 3 | 2011 | 1010 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2024 | 1010 | 0.040 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2022 | 180 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2020 | 71 | 0.040 |
Why?
|
| Prostate | 1 | 2023 | 423 | 0.040 |
Why?
|
| Patient Selection | 1 | 2003 | 709 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2020 | 363 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2019 | 35 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2019 | 2860 | 0.040 |
Why?
|
| Contrast Media | 1 | 2004 | 1096 | 0.040 |
Why?
|
| Receptor, ErbB-2 | 2 | 2012 | 280 | 0.040 |
Why?
|
| Radiotherapy, Conformal | 1 | 2019 | 89 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2012 | 3586 | 0.040 |
Why?
|
| Mastectomy | 3 | 2012 | 270 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2013 | 2781 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 3 | 2007 | 992 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2022 | 463 | 0.040 |
Why?
|
| China | 1 | 2019 | 264 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 1268 | 0.030 |
Why?
|
| Fluorouracil | 3 | 2011 | 555 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 191 | 0.030 |
Why?
|
| Cranial Irradiation | 1 | 2017 | 41 | 0.030 |
Why?
|
| Informed Consent | 1 | 2020 | 281 | 0.030 |
Why?
|
| Re-Irradiation | 1 | 2017 | 17 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 284 | 0.030 |
Why?
|
| Gynecomastia | 1 | 2017 | 8 | 0.030 |
Why?
|
| Canada | 2 | 2011 | 215 | 0.030 |
Why?
|
| Diffusion of Innovation | 1 | 2016 | 79 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2016 | 157 | 0.030 |
Why?
|
| Research Personnel | 1 | 2016 | 84 | 0.030 |
Why?
|
| Leucovorin | 2 | 2011 | 227 | 0.030 |
Why?
|
| Income | 1 | 2016 | 90 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2016 | 323 | 0.030 |
Why?
|
| Genomics | 1 | 2021 | 855 | 0.030 |
Why?
|
| Leuprolide | 1 | 2014 | 36 | 0.030 |
Why?
|
| Radiation Injuries | 1 | 2016 | 163 | 0.030 |
Why?
|
| Urban Population | 1 | 2016 | 240 | 0.030 |
Why?
|
| Information Dissemination | 1 | 1995 | 126 | 0.030 |
Why?
|
| Markov Chains | 1 | 2014 | 137 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2014 | 157 | 0.030 |
Why?
|
| Social Support | 1 | 2016 | 239 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 1998 | 682 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 1997 | 429 | 0.030 |
Why?
|
| Lung Volume Measurements | 1 | 2013 | 24 | 0.030 |
Why?
|
| Cytostatic Agents | 1 | 2012 | 4 | 0.020 |
Why?
|
| Cytotoxins | 1 | 2012 | 17 | 0.020 |
Why?
|
| Postmenopause | 1 | 2013 | 107 | 0.020 |
Why?
|
| Ethics, Medical | 1 | 1995 | 312 | 0.020 |
Why?
|
| Pemetrexed | 1 | 2012 | 76 | 0.020 |
Why?
|
| Glutamates | 1 | 2012 | 90 | 0.020 |
Why?
|
| Karnofsky Performance Status | 1 | 2012 | 44 | 0.020 |
Why?
|
| Sample Size | 1 | 2012 | 128 | 0.020 |
Why?
|
| Credentialing | 1 | 2012 | 14 | 0.020 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2012 | 86 | 0.020 |
Why?
|
| Bangladesh | 1 | 2013 | 339 | 0.020 |
Why?
|
| Body Surface Area | 1 | 2012 | 37 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2004 | 3651 | 0.020 |
Why?
|
| Taxoids | 1 | 2012 | 131 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2012 | 188 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 2 | 2005 | 501 | 0.020 |
Why?
|
| Levamisole | 1 | 2011 | 6 | 0.020 |
Why?
|
| Guanine | 1 | 2012 | 207 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2012 | 298 | 0.020 |
Why?
|
| Preoperative Period | 1 | 2012 | 98 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2012 | 215 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2007 | 2040 | 0.020 |
Why?
|
| Vincristine | 1 | 2011 | 113 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2012 | 179 | 0.020 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2011 | 21 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2005 | 244 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2011 | 132 | 0.020 |
Why?
|
| DNA Damage | 1 | 2012 | 392 | 0.020 |
Why?
|
| DNA Repair | 1 | 2012 | 376 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 305 | 0.020 |
Why?
|
| Glioma | 1 | 2012 | 321 | 0.020 |
Why?
|
| Senegal | 1 | 2009 | 4 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 458 | 0.020 |
Why?
|
| beta Catenin | 1 | 2011 | 267 | 0.020 |
Why?
|
| Nigeria | 1 | 2009 | 162 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2005 | 2092 | 0.020 |
Why?
|
| Health Surveys | 1 | 2009 | 245 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2005 | 2794 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2012 | 456 | 0.020 |
Why?
|
| Genetic Carrier Screening | 1 | 2008 | 59 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 2883 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2008 | 99 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2012 | 1351 | 0.020 |
Why?
|
| CpG Islands | 1 | 2007 | 169 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 1829 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2012 | 647 | 0.020 |
Why?
|
| Methotrexate | 2 | 1997 | 249 | 0.020 |
Why?
|
| Pedigree | 1 | 2008 | 982 | 0.020 |
Why?
|
| Data Collection | 1 | 2007 | 381 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2007 | 216 | 0.010 |
Why?
|
| Hydroxamic Acids | 1 | 2005 | 52 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 898 | 0.010 |
Why?
|
| Adolescent | 2 | 2009 | 9896 | 0.010 |
Why?
|
| Models, Econometric | 1 | 2005 | 15 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 2551 | 0.010 |
Why?
|
| Value of Life | 1 | 2005 | 23 | 0.010 |
Why?
|
| Stochastic Processes | 1 | 2005 | 79 | 0.010 |
Why?
|
| Gene Dosage | 1 | 2005 | 212 | 0.010 |
Why?
|
| Azacitidine | 1 | 2005 | 150 | 0.010 |
Why?
|
| Minority Groups | 1 | 2006 | 154 | 0.010 |
Why?
|
| ROC Curve | 1 | 2007 | 797 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2004 | 162 | 0.010 |
Why?
|
| BRCA1 Protein | 1 | 2005 | 215 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2008 | 565 | 0.010 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2004 | 19 | 0.010 |
Why?
|
| Interleukin-18 | 1 | 2004 | 29 | 0.010 |
Why?
|
| Lymphopenia | 1 | 2004 | 32 | 0.010 |
Why?
|
| Receptors, Interferon | 1 | 2004 | 34 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2007 | 938 | 0.010 |
Why?
|
| STAT1 Transcription Factor | 1 | 2004 | 58 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2008 | 1958 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2005 | 489 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2004 | 181 | 0.010 |
Why?
|
| Interleukin-12 | 1 | 2004 | 116 | 0.010 |
Why?
|
| Pyrroles | 1 | 2004 | 172 | 0.010 |
Why?
|
| Gadolinium DTPA | 1 | 2004 | 255 | 0.010 |
Why?
|
| Hospitals, University | 1 | 2003 | 199 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 2004 | 294 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2004 | 366 | 0.010 |
Why?
|
| Quality of Health Care | 1 | 2006 | 404 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2004 | 303 | 0.010 |
Why?
|
| Indoles | 1 | 2004 | 317 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 705 | 0.010 |
Why?
|
| Transfection | 1 | 2004 | 909 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2004 | 294 | 0.010 |
Why?
|
| Cognition | 1 | 2007 | 635 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2004 | 842 | 0.010 |
Why?
|
| Gene Expression | 1 | 2005 | 1322 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2007 | 1874 | 0.010 |
Why?
|
| Recurrence | 1 | 2004 | 1218 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 2008 | 828 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2004 | 483 | 0.010 |
Why?
|
| Meta-Analysis as Topic | 1 | 2001 | 84 | 0.010 |
Why?
|
| Alleles | 1 | 2004 | 1157 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2003 | 386 | 0.010 |
Why?
|
| Melanoma | 1 | 2004 | 497 | 0.010 |
Why?
|
| Liver | 1 | 2004 | 1238 | 0.010 |
Why?
|
| Animals | 2 | 2012 | 28945 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2004 | 771 | 0.010 |
Why?
|
| Genotype | 1 | 2004 | 1882 | 0.010 |
Why?
|
| Necrosis | 1 | 1999 | 210 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2004 | 2163 | 0.010 |
Why?
|
| Carcinoma, Lobular | 1 | 1999 | 85 | 0.010 |
Why?
|
| Neoplasm, Residual | 1 | 1999 | 194 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2004 | 793 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2004 | 1316 | 0.010 |
Why?
|
| Phenotype | 1 | 2004 | 2579 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2004 | 3490 | 0.010 |
Why?
|
| Child | 1 | 2007 | 7626 | 0.010 |
Why?
|
| Federal Government | 1 | 1995 | 29 | 0.010 |
Why?
|
| Government Regulation | 1 | 1995 | 50 | 0.010 |
Why?
|
| Endometrial Neoplasms | 1 | 1996 | 228 | 0.010 |
Why?
|
| Mice | 1 | 2004 | 12562 | 0.000 |
Why?
|